These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39033284)

  • 21. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
    Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
    JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis.
    Tincopa MA; Loomba R
    Semin Liver Dis; 2024 Jul; ():. PubMed ID: 38981691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers.
    Tsochatzis EA; Valenti L; Thiele M; Péloquin S; Lazure P; Masson MH; Allen AM; Lazarus JV; Noureddin M; Rinella M; Tacke F; Murray S
    Liver Int; 2024 Aug; 44(8):1990-2001. PubMed ID: 38634796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].
    Liu YX; Guo F; Niu LN; Zhang B; Dou J; Xu Q; Ning ZH; Wang XZ
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):346-353. PubMed ID: 38733190
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting.
    Gupta U; Ruli T; Buttar D; Shoreibah M; Gray M
    Am J Med Sci; 2024 Feb; 367(2):77-88. PubMed ID: 37967750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study.
    Kouvari M; Valenzuela-Vallejo L; Axarloglou E; Verrastro O; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Liver Int; 2024 Mar; 44(3):848-864. PubMed ID: 38263703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study.
    Gosnell JM; Golovko G; Arroyave E; Moghe A; Kueht ML; Saldarriaga OA; McKinney KH; Stevenson HL; Ferguson MR
    World J Diabetes; 2024 May; 15(5):886-897. PubMed ID: 38766421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
    Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
    J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Envisioning how to advance the MASH field.
    Allen AM; Younossi ZM; Diehl AM; Charlton MR; Lazarus JV
    Nat Rev Gastroenterol Hepatol; 2024 Oct; 21(10):726-738. PubMed ID: 38834817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
    Kanwal F; Shubrook JH; Adams LA; Pfotenhauer K; Wai-Sun Wong V; Wright E; Abdelmalek MF; Harrison SA; Loomba R; Mantzoros CS; Bugianesi E; Eckel RH; Kaplan LM; El-Serag HB; Cusi K
    Gastroenterology; 2021 Nov; 161(5):1657-1669. PubMed ID: 34602251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Siddiqui MS; Muthiah M; Satapathy SK; Patidar KR; Bhat M; Brandman D; Watt KD; Rinella M
    Hepatology; 2023 Dec; ():. PubMed ID: 38088872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Narro GEC; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    Ann Hepatol; 2024; 29(1):101133. PubMed ID: 37364816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.